Zika Breaking News

The Ministry of Health, Wellness, and Nutrition in Saint Lucia recently confirmed a laboratory-positive case of the Chikungunya, marking the first such case on the island since 2021. The patient ully recovered and been discharged.

As of March 6, 2026, local health authorities report no additional cases.

However, enhanced surveillance, contact tracing, and intensified mosquito control efforts are underway to prevent any potential spread. Aedes mosquitoes primarily spread Chikungunya, the same vectors that carry dengue and Zika. 

Despite this single case, tourism in Saint Lucia remains robust. the Saint Lucia Tourism Authority reported a record-breaking January 2026, which welcomed 37,691 stay-over arrivals. Saint Lucia continues to attract vacationers seeking its beaches, Pitons, luxury resorts, and eco-adventures. 

This growth was primarily driven by an 11% increase in visitors from the United States.

This isolated case comes amid broader regional increases in chikungunya virus activity across parts of the Caribbean and Americas, as noted in alerts from the Pan American Health Organization (PAHO).

The isolated chikungunya case has not triggered widespread PAHO advisories or reduced traveler activity in the Americas in 2026.

Vaccine and prevention recommendations remain important for both travelers and residents.

The chikungunya vaccine (VIMKUNYA) is approved in the United States for individuals aged 12 and older and is recommended for travelers to areas with ongoing chikungunya outbreaks or transmission.

Spanish health authorities have informed the European Centre for Disease Prevention and Control (ECDC) of a confirmed case of human infection with the swine influenza A(H1N1)v virus. 

This case was identified in February 2026 in the autonomous region of Catalonia. The patient remained completely asymptomatic, showing no flu-like symptoms such as fever, cough, or malaise, and has since made a full recovery. 

Notably, the individual had no known history of exposure to pigs, pig farms, or contaminated environments, which distinguishes this case from most previous zoonotic infections. As of March 3, 2026, all identified close contacts tested negative, and there was no evidence of secondary transmission.

This marks the fourth human case of swine influenza A(H1N1)v reported in Spain over the past 17 years. Fortunately, there has never been documented human-to-human transmission of the A(H1N1) virus in Spain.

Catalonia, located in the northeast, is one of Spain's most intensive pig-rearing regions and has recently faced separate challenges due to detections of African swine fever in wild boars in the Barcelona area. 

The ECDC's Communicable Disease Threats Report (Week 9, 2026) states, "Based on the information currently available, the likelihood of further transmission of variant A(H1N1) linked to this event is assessed to be very low."

According to the latest available data from the U.S. CDC, there have been no confirmed cases of variant swine-origin influenza (A(H1N1)v, A(H1N2)v, or A(H3N2)v) reported for the ongoing 2025–26 flu season.

However, during the 2024–2025 flu season, one confirmed human case of swine-origin variant A(H1N2)v infection was reported in Iowa. The adult patient was hospitalized but made a full recovery.

According to the U.S. CDC, seasonal influenza vaccines for 2026 provide no direct protection against swine-origin variant virus strains seen in recent European cases, as those belong to different genetic lineages.

A major study recently published in The Journal of Infectious Diseases details a significant measles transmission event linked to an unvaccinated adult who traveled from Europe to Colorado while infectious with the virus.

This article emphasizes the risks associated with air travel in spreading this highly contagious disease and underscores the essential role of vaccination.

The incident is described as one of the most extensive air travel-related measles transmission chains documented in the United States in recent years, with the virus spreading across flights, airport areas, and beyond.

However, as of March 3, 2026, there is no mandatory measles vaccination policy in the U.S. for domestic or international air travel when a person is departing from a measles outbreak area.

Investigators identified 135 travelers who were exposed through aircraft contact tracing. Ultimately, 15 secondary cases arose among those exposed: 5 during the international flight, 3 on the domestic flight, and 7 at the airport transit area. Additionally, 2 tertiary cases were linked to further community spread.

Notably, 5 of the secondary cases had documentation of at least one prior measles vaccination, indicating that breakthrough infections can occur.

The study's authors conclude that measles transmission can easily occur during travel in enclosed environments such as aircraft cabins, where the virus can remain airborne for up to two hours.

Most health agencies strongly recommend that all travelers aged 6 months and older receive measles vaccinations before international travel.

This outbreak highlights broader concerns about rising measles cases in the U.S. and globally, largely driven by gaps in vaccination coverage.

Public health experts worldwide continue to advocate for routine measles immunization as the most effective prevention strategy against such outbreaks.

On March 2, 2026, the U.S. Centers for Disease Control and Prevention acting director and head of the NIH, Jay Bhattacharya, MD, PhD, posted a video on X promoting the measles vaccine.

"Measles is preventable, and vaccination remains the most effective way to protect yourself and those around you," Dr. Bhattacharya stated.  

Venezuelan health authorities are addressing a significant resurgence of yellow fever (YF), with 36 laboratory-confirmed human cases since the outbreak began in mid-2025.

As of late February 2026, these mosquito-transmitted cases have been reported across 14 states, indicating a wide geographic spread that surpasses the more localized patterns seen in previous outbreaks.

So far, the disease has remained limited to forest exposures, with no evidence of urban transmission by Aedes aegypti mosquitoes.

Recent public reports have not detailed any related fatalities, though severe YF cases typically have a case-fatality rate of 20–50%.

Venezuela's YF outbreak occurs amid increased activity across the Americas. 

In 2024, the region reported 61 confirmed human cases and 30 deaths. By mid-2025, this number surged threefold to over 200 confirmed cases and 85 deaths (with a case-fatality rate of approximately 40%) across several countries, including Brazil, Colombia, Peru, Bolivia, and Ecuador, according to data from the Pan American Health Organization (PAHO).

Subsequent PAHO updates reported even higher totals, with YF outbreaks expanding beyond traditional Amazonian zones into new areas, including Colombia's Tolima department in 2026.

This resurgence serves as a stark reminder of yellow fever's capacity to exploit vaccination gaps in endemic settings.

According to the PAHO, the minimal childhood vaccination coverage—below 80% in Venezuela and several other endemic countries—coupled with climatic factors that favor mosquitoes, has contributed to the intensification of YF outbreaks.

PAHO has repeatedly assessed the risk of yellow fever outbreaks in the Americas as high and has issued multiple epidemiological alerts in 2025, urging mass vaccination in at-risk areas. In response to the current outbreak in Venezuela, emergency vaccination campaigns have been launched, targeting high-priority parishes, particularly in rural and border areas.

The single-dose Stamaril (YF-VAX) vaccine provides lifelong immunity. While proof of yellow fever vaccination is not required for direct arrivals to Venezuela from non-endemic countries like the United States, it is mandatory for travelers aged 1 year and older arriving from or transiting through countries with a risk of transmission, such as Brazil and Colombia.

As of March 2, 2026, the U.S. Centers for Disease Control and Prevention strongly recommends vaccination for most travelers visiting areas below approximately 2,300 meters in elevation, including popular sites like Angel Falls. In the U.S., the YF-VAX vaccine is commercially offered at travel clinics.

However, it is generally not recommended to vaccinate for travel limited to major cities such as Caracas or Valencia.

Separately, the U.S. Department of State maintains a Level 4: Do Not Travel advisory for Venezuela, citing severe risks to visitors in March 2026.

The U.S. government has confirmed today, March 1, 2026, that all international travel remains severely disrupted, and broader Middle Eastern airspace closures and restrictions have halted or rerouted thousands of flights across the region, causing significant global aviation chaos.

For example, the U.S. Embassy in Jerusalem announced it will remain closed on Monday, March 2, 2026, due to the deteriorating security situation. The announcement comes as U.S. government employees and their family members have been directed to continue sheltering in place at or near their residences until further notice.

"The U.S. Embassy is not in a position at this time to evacuate or directly assist Americans in departing Israel," the U.S. Embassy statement read.

U.S. citizens traveling abroad are encouraged to enroll in the Smart Traveler Enrollment Program to receive digital alerts, as the situation continues to develop rapidly and there is potential for further escalations in the region.

As travelers plan their visits to the Mid-Atlantic region in March 2026, health officials in Maryland report a notable increase in mumps infections this year.

According to the most recent data from the Maryland Department of Health (MDH), as of February 19, 2026, there have been 26 reported cases statewide, including 19 confirmed cases and 7 probable infections.

This marks a significant rise compared to just four confirmed cases throughout all of 2025.

The cases have primarily affected adults in the Baltimore metropolitan area, which includes Baltimore City and surrounding counties such as Anne Arundel, Baltimore, Carroll, Harford, Howard, and Queen Anne's.

Although mumps can occur in any age group across the state, no common link between the cases has been identified to date, despite ongoing investigations by MDH in coordination with local health departments.

MDH officials emphasize that the overall risk to the public remains low. While vaccination status is not specified for most or all cases in the available reports, Maryland's overall high vaccination rates contribute to the low general risk to the public.

This is positive news for the Baltimore Orioles, who are about to open their 2026 season.

Mumps is spread through direct contact with saliva or respiratory droplets from an infected person. It is less contagious than measles, but it can still pose risks, especially in close-contact settings like travel hubs, public transportation, or crowded tourist areas.

Most individuals recover fully from a mumps infection with supportive care, including rest, fluids, and over-the-counter pain relief. However, complications can arise, particularly in adults, says the MDH.

"The most effective prevention against a mumps infection is to get the Measles, Mumps, and Rubella vaccine," stated Dr. Meg Sullivan, Deputy Secretary for Public Health Services at MDH, in a press release.

"Talk with your health care provider about whether you and your family are up to date with the MMR vaccine. It is the most effective way to protect against all three viruses."

For international travelers heading to the greater Baltimore area, or any country reporting mumps outbreaks, Vax-Before-Travel recommends verifying vaccination status with a travel vaccine expert at least 2 weeks before departure.

The World Health Organization (WHO) today announced the recommended viral composition for influenza vaccines for the northern hemisphere influenza season of 2026-2027. This update aims to match the circulating strains better, enhancing protection against seasonal flu outbreaks.

For egg-based vaccines, the WHO recommends the following:

- An A/Missouri/11/2025 (H1N1)pdm09-like virus

- An A/Darwin/1454/2025 (H3N2)-like virus

- A B/Tokyo/EIS13-175/2025 (B/Victoria lineage)-like virus

For vaccines based on cell culture, recombinant protein, or nucleic acid, the WHO recommends:

- An A/Missouri/11/2025 (H1N1)pdm09-like virus

- An A/Darwin/1415/2025 (H3N2)-like virus

- A B/Pennsylvania/14/2025 (B/Victoria lineage)-like virus

The WHO reported that influenza A viruses were predominant, with other A(H3N2) and A(H1N1) variants also observed. Low levels of influenza B viruses (B/Victoria lineage) were detected, and no cases of B/Yamagata lineage viruses have been recorded since March 2020.

"Season after season, constantly evolving influenza viruses circulate globally, reminding us how interconnected our world is. Shared risks require shared action," stated Dr. Tedros Adhanom Ghebreyesus, WHO Director-General, in a press release on February 27, 2026.

These WHO recommendations guide national vaccine regulatory agencies and pharmaceutical companies worldwide in the development, production, and licensing of influenza vaccines for the upcoming season. This process ensures that vaccines are closely matched to the viruses expected to circulate, providing the best possible protection against severe illness and death.

To highlight the ongoing importance of flu vaccination, data from the U.S. Centers for Disease Control and Prevention (CDC) on vaccine effectiveness over the last three completed seasons in the USA show varying but significant levels of protection.

For the 2022-2023 season, the overall adjusted vaccine effectiveness was estimated at 30% (95% CI: -9%, 54%).

This improved to 44% (95% CI: 36%, 51%) in 2023-2024, and reached 56% (95% CI: 54%, 58%) in 2024-2025.

No official data has been posted for the 2025-2026 flu season.

These CDC figures underscore the vaccine's role in reducing flu-related hospitalizations and outpatient visits, even as effectiveness can fluctuate based on virus match and population factors.

As global travel increases, health experts emphasize the importance of timely vaccination, particularly for international travelers who may encounter diverse strains when visiting a different hemisphere.

The WHO's latest guidance helps travel clinics recommend flu shots amid an ever-changing influenza landscape.